Dr Lal Pathlabs

Which are the latest news on Dr Lal Pathlabs?

Why is Dr Lal Pathlabs Ltd falling/rising?

As of 05-Sep, Dr Lal Pathlabs Ltd's stock price is declining, currently at Rs 1,874.90, reflecting a 2.45% decrease. The stock has underperformed its sector and shows short-term weakness, with concerns about long-term growth and high valuation contributing to the downward trend.

As of 05-Sep, Dr Lal Pathlabs Ltd's stock price is falling, currently at Rs 1,874.90, which reflects a decrease of Rs 47.0 or 2.45%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed its sector by 0.33% today and reached an intraday low of Rs 1,854.4, marking a drop of 3.51%. <BR><BR>In terms of performance over the past week, the stock has decreased by 2.89%, while the benchmark Sensex has only fallen by 0.97%. Additionally, the stock's moving averages indicate that it is currently lower than its 5-day and 20-day moving averages, despite being above the 50-day, 100-day, and 200-day averages. This suggests a short-term weakness in price momentum.<BR><BR>Investor participation has seen a rise, with delivery volume increasing by 9.88% against the 5-day average, but the overall liquidity remains stable, indicating that trading activity is sufficient. However, the company's long-term growth prospects appear limited, as evidenced by a modest annual growth rate of 8.51% in net sales and 5.97% in operating profit over the last five years. The stock's high valuation, with a Price to Book Value of 12.7, further complicates its appeal, especially given that its profits have only risen by 9.9% over the past year, leading to a high PEG ratio of 5.8.<BR><BR>Overall, the combination of recent price declines, underperformance relative to the sector, and concerns regarding long-term growth and valuation contribute to the current downward movement in Dr Lal Pathlabs Ltd's stock price.

Who are in the management team of Dr Lal Pathlabs?

The management team of Dr Lal Pathlabs includes Arvind Lal (Chairman & Executive Director), Vandana Lal (Executive Director), Om Prakash Manchanda (Managing Director), and several independent and non-executive directors, bringing diverse expertise to the company.

The management team of Dr Lal Pathlabs includes the following key members:<BR><BR>1. **Arvind Lal** - Chairman & Executive Director<BR>2. **Vandana Lal** - Executive Director<BR>3. **Om Prakash Manchanda** - Executive Director & Managing Director<BR>4. **Archana Lal Erdmann** - Non-Executive Director<BR>5. **Rahul Sharma** - Non-Executive Director<BR>6. **Anoop Mahendra Singh** - Independent Director<BR>7. **Harneet Singh Chandhoke** - Independent Director<BR>8. **Sunil Varma** - Lead Independent Director<BR>9. **Saurabh Srivastava** - Independent Director<BR>10. **Somya Satsangi** - Independent Director<BR>11. **Rohit Bhasin** - Independent Director<BR>12. **Arun Duggal** - Independent Director<BR>13. **Gurinder Singh Kalra** - Independent Non-Executive Director<BR>14. **Rajit Mehta** - Independent Non-Executive Director<BR><BR>This diverse team brings a wealth of experience and expertise to the company.

What does Dr Lal Pathlabs do?

Dr. Lal PathLabs Ltd provides diagnostic and laboratory services in the healthcare sector, with a market cap of INR 32,242 Cr and reported net sales of 798 Cr and net profit of 170 Cr for June 2026. The company was founded in 1995 and became public in 2015.

Overview: <BR>Dr. Lal PathLabs Ltd operates in the healthcare services industry, providing diagnostic and laboratory services, and is categorized as a small-cap company.<BR><BR>History: <BR>The company was incorporated in 1995 as a Private Limited Company and later converted to a Public Limited Company in 2015. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 798 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 170 Cr (Quarterly Results - Jun 2026) <BR>Market cap: INR 32,242 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 58.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.83% <BR>Debt Equity: -0.45 <BR>Return on Equity: 21.01% <BR>Price to Book: 12.95<BR><BR>Contact Details: <BR>Address: E-2 Block Sector 18, Rohini New Delhi New Delhi : 110085 <BR>Tel: 91-011-3024 4149 <BR>Email: cs@lalpathlabs.com <BR>Website: http://www.lalpathlabs.com

Who are the peers of the Dr Lal Pathlabs?

Dr Lal Pathlabs' peers include Poly Medicure, Syngene Intl., Vijaya Diagnost., Indegene, Metropolis Healt, Suven Life Scie., Thyrocare Tech., and Vimta Labs. Most peers show Below Average growth and varying management risks, with Suven Life Scie. having the highest 1-year return at 84.49%, while Syngene Intl. has the lowest at -35.90%.

Peers: The peers of Dr Lal Pathlabs are Poly Medicure, Syngene Intl., Vijaya Diagnost., Indegene, Metropolis Healt, Suven Life Scie., Thyrocare Tech., and Vimta Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, Poly Medicure, Syngene Intl., Vijaya Diagnost., and Thyrocare Tech., while Good management risk is found at Indegene, Metropolis Healt, and the rest. Average management risk is present at Vimta Labs, and Suven Life Scie. shows Below Average management risk. All peers exhibit Below Average growth, with Dr Lal Pathlabs, Poly Medicure, Syngene Intl., Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., and Vimta Labs being categorized as Below Average, while Suven Life Scie. is also noted for Below Average growth. Excellent capital structure is reported for Dr Lal Pathlabs, Poly Medicure, Syngene Intl., Vijaya Diagnost., Thyrocare Tech., and Vimta Labs, while Average capital structure is seen at Indegene and Metropolis Healt, and Below Average capital structure is noted for Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 84.49%, while Syngene Intl. has the lowest at -35.90%. Dr Lal Pathlabs has a 1-year return of 17.15%, which is significantly higher than Syngene Intl. but lower than Suven Life Scie. Additionally, Metropolis Healt and Syngene Intl. are the only peers with negative six-month returns.

How big is Dr Lal Pathlabs?

As of 31st August, Dr Lal Pathlabs Ltd has a market capitalization of 32,242.00 Cr, with recent net sales of 2,890.80 Cr and a net profit of 541.90 Cr.

As of 31st August, Dr Lal Pathlabs Ltd has a market capitalization of 32,242.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2,890.80 Cr and a Net Profit of 541.90 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 2,508.14 Cr and Total Assets of 3,058.46 Cr.

Are Dr Lal Pathlabs Ltd latest results good or bad?

Dr. Lal PathLabs Ltd's latest Q1 FY27 results are strong, with a net profit of ₹169.50 crore (up 28.02% year-on-year) and revenue growth of 19.10% to ₹797.70 crore. The operating margin reached a record 31.03%, indicating robust profitability and a positive outlook for the company.

Dr. Lal PathLabs Ltd's latest results for Q1 FY27 are quite strong, indicating a positive performance overall. The company reported a net profit of ₹169.50 crore, which reflects a significant year-on-year growth of 28.02%. Additionally, revenue grew by 19.10% year-on-year, reaching ₹797.70 crore, showcasing robust operational performance.<BR><BR>The operating margin also reached an impressive 31.03%, marking the highest level in the company's history, which is a positive sign of profitability. Furthermore, the return on equity (ROE) stands at 21.01%, indicating strong capital efficiency.<BR><BR>Overall, the results highlight Dr. Lal PathLabs' ability to maintain consistent growth while achieving high profitability metrics, reinforcing its position as a leader in the healthcare services sector. The positive trends in revenue and margins suggest a strong operational leverage and a favorable outlook for the company moving forward.

Should I buy, sell or hold Dr Lal Pathlabs Ltd?

Has Dr Lal Pathlabs Ltd declared dividend?

Yes, Dr Lal Pathlabs Ltd has declared a dividend of 35% (₹7 per share) with an ex-date of February 5, 2026. The company has shown positive total returns over the past 2 to 5 years, despite recent short-term declines.

Dr Lal Pathlabs Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 35%<BR>- Amount per share: 7<BR>- Ex-date: 05 Feb 26<BR><BR>Dividend Yield: 0.91%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -7.73%, the dividend return was 0.65%, resulting in a total return of -7.08%.<BR><BR>Over the past 6 months, the price return was -7.94%, the dividend return was 1.03%, leading to a total return of -6.91%.<BR><BR>In the last year, the price return was -1.01%, the dividend return was 1.61%, culminating in a total return of 0.6%.<BR><BR>Over the past 2 years, the price return was 15.29%, the dividend return was 4.76%, resulting in a total return of 20.05%.<BR><BR>In the last 3 years, the price return was 38.36%, the dividend return was 6.56%, leading to a total return of 44.92%.<BR><BR>Over the past 4 years, the price return was 1.02%, the dividend return was 5.75%, culminating in a total return of 6.77%.<BR><BR>In the last 5 years, the price return was 26.82%, the dividend return was 7.75%, resulting in a total return of 34.57%.<BR><BR>Overall, Dr Lal Pathlabs Ltd has declared a significant dividend and has shown positive total returns over longer periods, particularly in the 2 to 5-year ranges, indicating a favorable performance for investors.

Is Dr Lal Pathlabs technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish, supported by daily moving averages, though caution is advised due to mixed signals from weekly indicators.

As of 1 December 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating a bullish trend. However, the weekly MACD and Bollinger Bands are both mildly bearish, suggesting some caution in the short term. The monthly indicators, including MACD and Bollinger Bands, are bullish, indicating a stronger long-term outlook. Overall, while there are mixed signals, the prevailing trend is mildly bullish, driven primarily by daily moving averages.

How has been the historical performance of Dr Lal Pathlabs?

Dr Lal Pathlabs has exhibited consistent growth in net sales and profits, with net sales increasing from ₹1,203.40 Cr in March 2019 to ₹2,461.40 Cr in March 2025, and profit after tax rising from ₹200.50 Cr to ₹492.20 Cr during the same period. The company's earnings per share improved from 23.91 to 58.27, reflecting strong overall performance.

Answer:<BR>The historical performance of Dr Lal Pathlabs shows a consistent growth trajectory in net sales and profits over the years, with significant increases noted in the latest fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Dr Lal Pathlabs has demonstrated robust growth in net sales, rising from 1,203.40 Cr in March 2019 to 2,461.40 Cr in March 2025. The total operating income followed a similar upward trend, reaching 2,461.40 Cr in March 2025, up from 1,203.40 Cr in March 2019. Operating profit, excluding other income, also increased significantly, from 343.60 Cr in March 2020 to 695.50 Cr in March 2025. The profit before tax saw a substantial rise from 300.60 Cr in March 2019 to 624.70 Cr in March 2025, while profit after tax increased from 200.50 Cr to 492.20 Cr in the same period. The company's earnings per share (EPS) improved markedly from 23.91 in March 2019 to 58.27 in March 2025, reflecting enhanced profitability. On the balance sheet, total assets grew from 1,351.46 Cr in March 2020 to 2,630.17 Cr in March 2025, while total liabilities rose from 1,351.46 Cr to 2,630.17 Cr, indicating a proportional increase in both assets and liabilities. Cash flow from operating activities also showed improvement, increasing from 283.00 Cr in March 2020 to 568.00 Cr in March 2025, although the net cash outflow was recorded at -68.00 Cr in March 2025. Overall, Dr Lal Pathlabs has shown a strong performance with consistent growth in sales, profits, and assets over the years.

Who are the top shareholders of the Dr Lal Pathlabs?

The top shareholders of Dr Lal Pathlabs include Arvind Lal with 30.8%, foreign institutional investors holding 23.91%, mutual funds at 12.84%, and Invesco Oppenheimer International Growth Fund as the largest public shareholder with 3.52%. Individual investors own a total of 4.11%.

The top shareholders of Dr Lal Pathlabs include the promoters, with Arvind Lal being the individual with the highest holding at 30.8%. Additionally, institutional investors play a significant role, with foreign institutional investors (FIIs) holding 23.91% through 326 different entities. Mutual funds are represented by 26 schemes, accounting for 12.84% of the shares. The highest public shareholder is Invesco Oppenheimer International Growth Fund, which holds 3.52%. Individual investors collectively own 4.11% of the company.

Is Dr Lal Pathlabs overvalued or undervalued?

As of March 21, 2024, Dr. Lal Pathlabs is considered very expensive and overvalued with a PE ratio of 48.96, despite being more attractive than some competitors like Max Healthcare and Apollo Hospitals, but its growth potential is questionable given a PEG ratio of 1.36 and a low dividend yield of 1.05%.

As of 21 March 2024, the valuation grade for Dr. Lal Pathlabs has moved from expensive to very expensive, indicating a significant shift in its market positioning. The company is currently deemed overvalued. Key ratios include a PE ratio of 48.96, an EV to EBITDA of 32.84, and a Price to Book Value of 10.98, all of which suggest a premium valuation compared to its peers.<BR><BR>In comparison, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals stands at 69.03, illustrating that Dr. Lal Pathlabs, despite its high valuation, is still more attractive than some competitors. However, with a PEG ratio of 1.36 and a dividend yield of only 1.05%, the stock's growth potential does not justify its current price. Recent performance shows that while Dr. Lal Pathlabs has outperformed the Sensex over the past week and month, it lags behind in the year-to-date and one-year returns, reinforcing the notion that it may be overvalued in the current market context.

When is the next results date for Dr Lal Pathlabs?

No Upcoming Board Meetings